Preservation of immature hematopoietic progenitor cells responding to interleukin 3 in marrow treated with 4-hydroperoxycyclophosphamide.

Minegishi, Naoko; Minegishi, Masayoshi; Tuchiya, Shigeru; Konno, Tasuke

doi:10.1620/tjem.159.113

Cited by 2 publications

(3 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The addition of RBC to make 7% RBC suspension is reported to be important to minimize the damage of 4HC to normal hematopoietic progenitor cells ). We also proved previously that 4HC treatment (100 ,u g/ml) in the presence of 7% suspension of RBC could preserve immature hematopoietic stem cells that form colonies under the condition containing interleukin 3 and erythropoietin (Minegishi et al 1989). On the other hand, 4HC effects on leukemic cells will be also reduced under the condition containing 7% RBC from the same reason.…”

Section: Discussionsupporting

confidence: 70%

“…However, after treatment with 4HC at 100 pug/m1,10 of 13 cases (UPN 1, 3, 4, 5, 7, 8,10,11,12 and 13) had no detectable colonies, and 2 AML samples had few colonies that were only 0.055% (UPN 2) and 0.26% (UPN 6) as compared with those of untreated cultures. According to the same experimental condition described in this paper, approximatly 10 to 40% of normal hematopoietic progenitor cells supported by a combination of interleukin 3 and erythropoietin were survived even after treatment with 100 p g/ml of 4HC according to the same incubation condition described in this paper (Minegishi et al 1989). …”

Section: Resultsmentioning

confidence: 61%

“…The treatment of a mixture of 2 x 10' ml BM nucleated cells and 7% suspension of packed RBC with 4HC at 100 p g/ml has been recommended for the purging protocol for autologous bone marrow transplantation . Based on these clinical data, recent work from our institution showed that the 4HC treatment with the methods according to Jones et al, preserved immature hematopoietic progenitor cells responding to interleukin 3 (Minegishi et al 1989). In this report, we also determined in in vitro experiment that hyperthermia and 4-HC could be efficiently used to eliminate leukemic progenitor cells obtained from BM and peripheral blood of leukemic patients.…”

mentioning

confidence: 60%

See 2 more Smart Citations

Effects of in vitro treatment with 4-hydroperoxycyclophosphamide and hyperthermia on leukemic progenitor cells.

Minegishi

Tsuchiya

et al. 1989

Tohoku J. Exp. Med.

Self Cite

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 70%

Section: Resultsmentioning

confidence: 61%

mentioning

confidence: 60%

See 1 more Smart Citation

Effects of in vitro treatment with 4-hydroperoxycyclophosphamide and hyperthermia on leukemic progenitor cells.

Minegishi

Tsuchiya

et al. 1989

Tohoku J. Exp. Med.

Self Cite

View full text Add to dashboard Cite

Isolation and Characterization of Two Monoclonal Antibodies that Recognize Different Epitopes of the Human c-kit Receptor.

Morita

Tsuchiya

Fujie

et al. 1996

Tohoku J. Exp. Med.

View full text Add to dashboard Cite

After immunizing mice with a human megakaryoblastic leukemia cell line, M-MOK, we obtained two monoclonal antibodies which recognize the human c-kit receptor. The monoclonal antibodies, designated MTK1 and MTK2, were found to specifically recognize Balb/3T3 cells transfected with human c-kit cDNA and not parent Balb/3T3 cells while showing different immunological, biochemical and biological behaviors. Both allowed visualization of the 140 kDa c-kit protein by Western blot analysis, but MTK1 detected only positive band with non-reducing conditions for sodium dodecyl sulfate-polyacrylamide gel electrophoresis. MTK1 partially inhibited the stem cell factor (SCF) induced proliferation of M-MOK cells, whereas, MTK2 was without effect. MTK1 also inhibited the bone marrow derived colony forming unit granulocyte/macrophage (CFU-GM) formed by granulocyte-macrophage colony stimulating factor (GM-CSF) and SCF. Not only anti-CD34 antibodies (HPCA-1) but also MTK1 could be shown to concentrate bone marrow CFU-GM and burst forming unit erythroid (BFU-E) effectively. The presently described monoclonal antibodies may therefore be useful for functional analysis of the ligand binding domain of the human c-kit receptor, as well as for further classification of hematopoietic stem cells in addition to the CD34 positive cells.

show abstract

Preservation of immature hematopoietic progenitor cells responding to interleukin 3 in marrow treated with 4-hydroperoxycyclophosphamide.

Cited by 2 publications

References 11 publications

Effects of in vitro treatment with 4-hydroperoxycyclophosphamide and hyperthermia on leukemic progenitor cells.

Effects of in vitro treatment with 4-hydroperoxycyclophosphamide and hyperthermia on leukemic progenitor cells.

Isolation and Characterization of Two Monoclonal Antibodies that Recognize Different Epitopes of the Human c-kit Receptor.

Contact Info

Product

Resources

About